```html

Watanabe Disease (Lipoprotein Lipase Deficiency)

Overview

Watanabe disease, also known as familial chylomicronemia syndrome (FCS) or lipoprotein lipase (LPL) deficiency, is a rare, autosomal‑recessive genetic disorder that prevents the body from breaking down triglyceride‑rich lipoproteins (chylomicrons). The result is extremely high levels of triglycerides in the blood, which can cause recurrent pancreatitis, eruptive skin lesions, and other systemic problems.

• Who it affects: Both males and females of any ethnicity. The condition is inherited when a child receives two defective copies of the LPL gene (one from each parent). Consanguineous (related) marriages increase the likelihood.
• Prevalence: Estimated at 1‑2 per million people worldwide, though exact numbers vary because many cases remain undiagnosed. In Japan, where the disease was first described by Dr. Watanabe in 1960, prevalence is slightly higher (≈ 1 per 600 000) due to founder mutations.<sup>[1] WHO, 2022</sup>
• Age of onset: Typically in infancy or early childhood when triglyceride levels become dangerously high; however, milder cases may present in adolescence or adulthood.

Symptoms

Because LPL deficiency disrupts the clearance of chylomicrons, symptoms relate to hypertriglyceridemia and its downstream effects. The clinical picture can be variable, but most patients experience a combination of the following:

Acute and chronic symptoms

• Recurrent abdominal pain – often the first sign, caused by pancreatitis. Pain may be severe, radiating to the back, and associated with nausea/vomiting.
• Eruptive xanthomas – small, yellow‑red papules on the buttocks, extensor surfaces, or trunk, representing lipid deposits.
• Lipemia retinalis – milky appearance of retinal vessels observed on eye exam when triglycerides exceed 2 000 mg/dL.
• Hepatosplenomegaly – enlarged liver and spleen due to lipid accumulation.
• Fatty stools (steatorrhea) – malabsorption of fat because chylomicrons are not cleared efficiently.
• Growth retardation – especially in infants, due to chronic malnutrition and metabolic stress.
• Neurological signs – rare, but may include ataxia or peripheral neuropathy from severe hypertriglyceridemia.

Laboratory findings

• Serum triglyceride levels often > 1 000 mg/dL; values > 2 000 mg/dL are classic.
• Milky or “creamy” plasma that separates on centrifugation.
• Low or absent lipoprotein lipase activity measured in post‑heparin plasma.

Causes and Risk Factors

Genetic cause

• Mutations in the LPL gene (chromosome 8p22) that encode the enzyme lipoprotein lipase. Over 200 pathogenic variants have been identified, including missense, nonsense, splice‑site, and deletion mutations.
• In rarer cases, deficiency can arise from defective genes that encode proteins necessary for LPL activity, such as APOA5, GPIHBP1, or LMF1. These are collectively referred to as “secondary LPL pathway defects.”<sup>[2] NIH Genetic Testing Registry, 2023</sup>

Risk factors

• Consanguinity or family history of early‑onset pancreatitis.
• Ethnic groups with known founder mutations (e.g., certain Japanese, French‑Canadian, and Arab populations).
• Secondary contributors that can worsen triglyceride levels: uncontrolled diabetes, excess alcohol, high‑fat diet, certain medications (e.g., isotretinoin, estrogen therapy).

Diagnosis

Diagnosis rests on a combination of clinical suspicion, laboratory evaluation, and genetic confirmation.

Initial laboratory work‑up

1. Fasting lipid panel – reveals markedly elevated triglycerides with normal or low LDL‑C.
2. Post‑heparin plasma LPL activity – heparin releases endothelial LPL into circulation; activity < 10 % of normal supports deficiency.
3. Serum amylase / lipase – may be elevated during pancreatitis episodes.

Imaging

• Abdominal CT or MRI to assess pancreatitis severity.
• Ophthalmologic exam for lipemia retinalis.

Genetic testing

Sequencing of the LPL gene (or a multigene panel for hypertriglyceridemia) is the definitive test. Identification of pathogenic biallelic variants confirms the diagnosis and guides family counseling.

Differential diagnosis

Other causes of severe hypertriglyceridemia must be excluded, including:

• Familial hypertriglyceridemia (polygenic)
• Secondary hypertriglyceridemia (e.g., uncontrolled diabetes, medications, hypothyroidism)
• Other rare lipase deficiencies (e.g., hepatic lipase deficiency)

Treatment Options

Management has three goals: lower triglycerides, prevent pancreatitis, and address long‑term organ complications.

Dietary therapy (first‑line)

• Very low‑fat diet – <10 % of total daily calories (< 20 g fat/day) to reduce chylomicron formation.
• Medium‑chain triglyceride (MCT) oil – absorbs directly into portal circulation, bypassing the LPL pathway, providing a safe caloric source.
• Frequent, small meals (5‑6 per day) to avoid post‑prandial triglyceride spikes.
• Limit simple sugars and alcohol, both of which can raise triglycerides.

Pharmacologic options

1. Volanesorsen (antisense oligonucleotide) – reduces apolipoprotein C‑III, a key inhibitor of LPL. FDA approved (2021) for FCS; lowers triglycerides by up to 70 % in clinical trials.<sup>[3] Mayo Clinic, 2022</sup>
2. Omega‑3 fatty acid ethyl esters (e.g., icosapent ethyl) – modest triglyceride reduction; adjunctive only.
3. Fibrates (fenofibrate, gemfibrozil) – generally ineffective in true LPL deficiency but may help if residual enzyme activity exists.
4. Statins – used primarily for cardiovascular risk management; do not lower triglycerides dramatically in FCS.

Procedural/Advanced therapies

• Lipoprotein apheresis – extracorporeal removal of triglyceride‑rich plasma; reserved for refractory cases or acute crises.
• Liver transplantation – curative because the liver synthesizes functional LPL; considered only in life‑threatening disease unresponsive to other measures.

Acute pancreatitis management

During an episode, standard care includes nil per os (NPO), aggressive IV fluid resuscitation, analgesia, and, when needed, ICU monitoring. Rapid reduction of triglycerides (e.g., insulin infusion, heparin drip, or apheresis) can be employed under specialist supervision.

Living with Watanabe Disease (Lipoprotein Lipase Deficiency)

Because the condition is lifelong, patients benefit from a structured, multidisciplinary approach.

Practical daily tips

• Meal planning – work with a registered dietitian experienced in low‑fat nutrition. Use food‑tracking apps to stay < 20 g fat/day.
• Hydration – aim for ≥ 2 L water daily; dehydration can exacerbate hypertriglyceridemia.
• Physical activity – moderate aerobic exercise (e.g., brisk walking 30 min most days) improves insulin sensitivity and helps keep triglycerides lower.
• Medication adherence – never miss doses of volanesorsen or other agents; set reminders.
• Regular monitoring – fasting triglyceride check every 1‑3 months, liver function tests for volanesorsen (risk of hepatic steatosis), and annual eye exams.
• Family screening – test siblings and parents for carrier status; genetic counseling is essential for reproductive planning.
• Travel preparations – bring a written “low‑fat diet” letter for airlines, keep MCT oil and any emergency meds accessible.

Psychosocial support

Living with a restrictive diet can be isolating. Consider joining rare‑disease support groups (e.g., FCS Foundation) and seeking mental‑health counseling if anxiety or depression develops.

Prevention

Because the primary cause is genetic, primary prevention is limited. However, the following strategies can reduce the risk of complications:

• Early diagnosis through newborn screening in high‑risk families (available in some countries).
• Adhering strictly to low‑fat dietary recommendations from the time of diagnosis.
• Avoiding secondary triglyceride‑raising factors: uncontrolled diabetes, excess alcohol, high‑sugar diets, and certain medications.
• Prompt treatment of any acute pancreatitis to prevent recurrence.

Complications

If untreated or poorly controlled, severe hypertriglyceridemia can lead to:

• Recurrent acute pancreatitis – may progress to chronic pancreatitis, exocrine insufficiency, and diabetes mellitus.
• Pancreatic necrosis or pseudocyst formation – life‑threatening emergencies.
• Cardiovascular disease – while LPL deficiency is more associated with pancreatitis, chronic lipid abnormalities increase atherosclerotic risk.
• Hepatic steatosis and fibrosis – due to fatty infiltration.
• Growth failure in children – from chronic malnutrition.
• Neurological impairment – rare, but can stem from severe hyperviscosity.

When to Seek Emergency Care

References

1. World Health Organization. Rare Diseases: Global Prevalence and Research Priorities. WHO Press; 2022.
2. National Institute of Health. Genetic Testing Registry. “Lipoprotein Lipase Deficiency.” Updated 2023.
3. Mayo Clinic. “Volanesorsen for Familial Chylomicronemia Syndrome.” Clinical Review, 2022.

```